Neurovascular Effects of Empagliflozin

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
Kanokwan Bunsawat
Study ID
NCT07799441
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Blood Pressure
  • Endothelial Dysfunction

Eligibility Criteria

Sex
ALL
Age
45 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The goal of this clinical trial is to examine whether empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, improves vascular and autonomic function in adults with prehypertension. The main questions this clinical trial aims to answer are: 1. Does empagliflozin improve endothelial function? 2. Does empagliflozin improve sympathetic nervous system function? This clinical trial employs a double-blind, placebo-controlled crossover study lasting up to 6 weeks for participants with prehypertension and up to 2 weeks for normotensive participants. Participants with prehypertension will take empagliflozin or placebo for 2 weeks, separated by a 2-week washout. Normotensive participants will complete baseline, pre-treatment visits only and will serve as a control group.

Key Dates

First listed
Sep 2, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Sep 30, 2028
Completion
Jan 31, 2029

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin
    Participants will receive Empagliflozin (25 mg once a day) for 2 weeks.
  • Placebo Comparator: Placebo
    Participants will receive placebo pills identical in appearance and taste.

Primary Outcome Measure

Macrovascular endothelial function as assessed by brachial artery flow-mediated dilation (FMD) [ Time Frame: At the end of each 2-week treatment period ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Integrative Neurovascular Physiology Laboratory - University of IowaIowa CityIowa52242
Kanokwan Bunsawat, PHD
[email protected]
3193351859
Nicholas Carlini, PHD
[email protected]
484-947-7574

Find similar trials in Iowa City, IA

By research site
Integrative Neurovascular Physiology Laboratory - University of Iowa· Iowa City, IA

Related Studies